NR2F6 as a Prognostic Biomarker in HNSCC

Area of Science:

• Oncology
• Immunology

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer with a poor prognosis.
• Nuclear receptor 2F6 (NR2F6) functions as an immune checkpoint molecule, linked to adverse outcomes in various cancers.
• The prognostic significance of NR2F6 in HNSCC remains underexplored.

Purpose of the Study:

• To investigate the prognostic value of NR2F6 expression in a cohort of HNSCC patients.
• To determine the association between NR2F6 expression and the development of local recurrence and survival outcomes.

Main Methods:

• Utilized a cohort of 383 clinically characterized HNSCC patients.
• Assessed NR2F6 expression in primary tumors via immunohistochemistry.
• Correlated NR2F6 expression with clinical characteristics and clinicopathological features, including local recurrence and survival.

Main Results:

• Primary tumors from patients experiencing local recurrence exhibited higher NR2F6 expression.
• Elevated NR2F6 expression was significantly associated with reduced recurrence-free survival.
• No significant correlation was found between NR2F6 expression and overall survival.
• NR2F6 expression levels were independent of tumor (T) stage and Union for International Cancer Control (UICC) stage.

Conclusions:

• NR2F6 may serve as a novel prognostic biomarker for early detection of local recurrences in HNSCC.
• Identifying patients with high NR2F6 expression could facilitate more frequent follow-up, potentially improving patient management.